top of page

THE AVISI0™ FOXC1 TECHNOLOGY

The Forkhead Box C1 Gene (FOXC1)

FOX (Forkhead box) C1 gene belongs to the forkhead family of transcription factors characterized by a distinct DNA-binding fork head domain.  FOX proteins regulate the expression of genes involved in embryonic development,  cell growth, proliferation, differentiation, and longevity.  We have demonstrated:

​

FOXC1 is an excellent theranostic biomarker specific for BLBC. [1]

 

Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. [2]

 

FOXC1 mediates PIN 1 expression, which in turn stabilizes p65/RelA protein and activates the transcription factor NF-κB in BLBC cells. [3] [Gene expression microarray data] [Immunoprecipitation] [Immunoblotting]

 

Identified a novel EGFR-FOXC1 signaling axis critical for BLBC cell function. [4]

  • Both FOXC1 mRNA and protein levels significantly correlated with EGFR expression in human breast tumors. EGFR activation induced FOXC1 transcription through the ERK and Akt pathways in BLBC. EGFR inhibition in vivo reduced FOXC1 expression in xenograft tumors. We also found that FOXC1 knockdown impaired the effects of EGF on BLBC cell proliferation, migration, and invasion.[Immunoprecipitation] [Immunoblotting] [qRT-PCR] [Luciferase activity] [Xenograph]

FOXC1 IHC detection is a significant independent prognostic biomarker superior to existing surrogates. [5]

  • FOXC1 overexpression reduces sensitivity to anti-Hedgehog inhibitors  in BLBC cells. [6]

  • FOXC1 expression on immunohistochemical staining is associated with BRCA1 vs BRCA2 mutations (30/46 vs. 6/35) [7]

  • In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib [7]

  • Use of FOXC1 as a prognostic biomarker for Acute Myeologenous Leukemia. [8]

Partha S. Ray, MD

Founder,  Director, Chairman-Med/Sci Advisory Board

FOXC1 TECHNOLOGY

 

Interviewed by

Jim Fitzpatrick:

We believe that FOXC1 imparts a property whereby the cell is specialized from the beginning.  Contrary to other forms of cancer, requiring adaptation to environment before metastasis, BLBC tumors can be very small, do not clinically demonstrate spread to regional lymph nodes, but yet have already metastasized via the blood stream to distant organs, thus eluding detection until it is too late.

bottom of page